Every 8-K that Nuvation Bio Inc (NUVB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NUVB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUVB filings page.
Nuvation Bio Inc. reported second quarter 2026 results with total revenue of $31.7 million, driven by $23.2 million in net product revenue from IBTROZI (taletrectinib) and $8.5 million from collaboration and license agreements. IBTROZI is described as the most prescribed ROS1 TKI in first-line and overall new ROS1+ NSCLC patient starts in 2026, with roughly 85% of about 160 new patients TKI‑naive.
The company recorded a net loss of $62.8 million, or $0.18 per share, as research and development expenses reached $30.7 million and selling, general and administrative costs were $42.6 million. Cash, cash equivalents and marketable securities totaled $661.0 million as of June 30, 2026, with an additional $36.5 million in net proceeds from a July 2026 exercise of the convertible senior notes overallotment option.
Nuvation highlighted updated long‑term Phase 2 data for investigational IDH1 inhibitor safusidenib and plans to expand its clinical program across IDH1‑mutant glioma. Multiple Phase 2 and Phase 3 trials continue for IBTROZI in ROS1+ NSCLC, including the global TRUST program, alongside the Phase 3 SIGMA study evaluating safusidenib as maintenance therapy in high‑risk IDH1‑mutant astrocytoma.
Nuvation Bio Inc. has fully closed a registered underwritten offering of $287.5 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, including a $37.5 million greenshoe exercised by underwriters.
The company expects net proceeds of about $277.6 million after fees. It used roughly $2.2 million of the greenshoe proceeds to purchase additional capped call transactions designed to lessen potential dilution or higher cash payments upon note conversion, and plans to deploy the remaining funds for general corporate purposes such as working capital, operating expenses, capital expenditures, and administrative costs.
Nuvation Bio Inc. completed an underwritten public offering of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, with underwriters holding a 30‑day option to buy up to an additional $37.5 million of notes. The notes are unsecured, pay interest semiannually, and are convertible into cash, Class A common stock, or a combination, at the company’s election.
The initial conversion rate is 127.4941 shares per $1,000 of notes, implying a conversion price of about $7.84 per share, a 35.0% premium to the June 25, 2026 share price. Nuvation Bio estimates net proceeds of $241.2 million, used to fund $14.9 million of capped call transactions and to repay in full about $58.5 million under its senior secured loan agreement, with the balance for general corporate purposes.
Nuvation Bio Inc. reported the results of its 2026 Annual Meeting of Stockholders. Holders of 389,931,796 shares were present in person or by proxy, representing 83.6% of the Class A Common Stock and 100% of the Class B Common Stock outstanding as of March 25, 2026, which constituted a quorum.
Stockholders elected Class A directors Robert B. Bazemore, Jr. and Robert Mashal, M.D., and Class B director Kim Blickenstaff to serve until the 2029 annual meeting and until their successors are elected and qualified. Stockholders also ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
On an advisory basis, stockholders approved the compensation of the Company’s named executive officers as disclosed in the April 10, 2026 proxy statement. All three proposals received sufficient votes for approval.
Nuvation Bio reported a strong first quarter of 2026, moving to net income of $5.4 million after a net loss of $53.2 million a year earlier. Total revenue rose to $83.2 million, driven by initial U.S. sales of IBTROZI and a large increase in collaboration and license revenue.
Net product revenue from U.S. sales of IBTROZI (taletrectinib) reached $18.5 million, while collaboration and license agreements revenue climbed to $64.7 million, largely due to an upfront payment under the Eisai agreement. The company ended March 31, 2026 with $533.7 million in cash, cash equivalents, and marketable securities.
Nuvation Bio highlighted updated clinical data showing durable responses for IBTROZI in ROS1‑positive NSCLC and announced acquisition of Japan rights to safusidenib, supporting its global development. Research and development spending increased to $35.0 million, and selling, general and administrative expenses were $38.3 million as the company invests behind its oncology portfolio.
Nuvation Bio Inc. reported fourth-quarter and full-year 2025 results, highlighting the first commercial contributions from IBTROZI and stronger collaboration revenue. Net product revenue from U.S. sales of IBTROZI reached $15.7 million in Q4 and $24.7 million for 2025.
Total revenue rose to $41.9 million in Q4 and $62.9 million for 2025, driven by a $25 million milestone from Nippon Kayaku and higher license, service, supply and royalty revenue. The company ended 2025 with $529.2 million in cash, cash equivalents and marketable securities and reported a narrower full-year net loss of $204.6 million, or $(0.60) per share, compared with a $567.9 million loss in 2024.
Nuvation Bio Inc. entered into a License and Collaboration Agreement with Eisai Co., Ltd. covering taletrectinib in a broad Territory including Europe, parts of the Middle East, Africa, Asia-Pacific, Canada and other countries. Eisai will pay Nuvation Bio upfront consideration of €50 million, a near-term regulatory milestone of €25 million, and up to an aggregate of €120 million tied to sales milestones, plus tiered royalties in the low- to high-teens on annual net sales of licensed products.
The agreement lasts on a product-by-product basis through the applicable royalty term, after which Eisai’s license becomes non-exclusive and royalty-free for that product. Eisai and Nuvation Bio each have defined termination rights, including for material breach, certain safety issues, failure to obtain specified EU regulatory approvals by a set date, invalidation of fundamental patents in a country, or bankruptcy. Nuvation Bio also reported that it released a press release with preliminary unaudited year-end cash, cash equivalents and marketable securities and preliminary net product revenue of IBTROZI, and furnished a joint press release and an updated corporate presentation.
Nuvation Bio Inc. announced it is discontinuing development of NUV-1511, the first compound from its drug-drug conjugate platform, due to a lack of sufficiently consistent efficacy across patient cohorts, despite being well tolerated and showing promising signals in some patients. The company plans to use knowledge from this program to design new DDC candidates and will reallocate the $100-150 million of projected NUV-1511 R&D and CMC costs through 2029 to other pipeline molecules and next-generation DDC programs. Nuvation Bio highlighted ongoing initiatives, including a global randomized G203 trial of safusidenib in high-risk IDH1-mutant glioma and continued investment in the commercial launch and development of IBTROZI (taletrectinib), such as the TRUST-IV study in early-stage ROS1+ non-small cell lung cancer. The company also furnished an updated corporate presentation to accompany these updates.
Nuvation Bio Inc. released an updated corporate presentation and highlighted newly published positive Phase 2 data for its IDH1 inhibitor safusidenib in Japanese patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas. In an open-label study of 27 patients, safusidenib achieved an objective response rate of 44.4%, and median duration of response was not yet estimable because no progression had occurred. As of the data cut-off on March 10, 2023, median progression-free survival had not been reached, with 87.9% of patients progression free at 24 months and median follow-up of 28 months, suggesting durable disease control.
Adverse events were mostly mild to moderate; grade 3 or higher treatment-related events occurred in 18.5% of patients, with no grade 5 events and 11.1% discontinuations. A Good Clinical Practice noncompliance issue in adverse event collection was addressed through re-investigation and re-collection of safety data. Nuvation Bio is advancing the G203 global randomized study of safusidenib as maintenance therapy in high-grade and high-risk grade 2 IDH1-mutant gliomas, with a protocol amendment to finalize it as a global Phase 3 trial. The primary endpoint is progression-free survival by blinded central review, which the U.S. Food and Drug Administration has agreed could support full approval.
Nuvation Bio Inc. furnished a press release announcing its financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 to this Form 8-K and, along with the related information, is furnished rather than filed under the Exchange Act and Securities Act, except as specifically incorporated by reference. The company’s Class A Common Stock (NUVB) and Redeemable Warrants (NUVB.WS) are listed on the NYSE.